These preclinical studies have led to a phase I clinical trial of a clinically approved poly (ADP-ribose) polymerase 1 inhibitor (olaparib) for the treatment of pulmonary arterial hypertension, which will be completed in 2019 (https://clinicaltrials.gov/ct2/show/NCT03251872). The gene discussed is PARP1; the disease is pulmonary arterial hypertension.